Table 3 Cox regression of clinical outcome
Univariable | Multivariable | |||
|---|---|---|---|---|
Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | P-value | |
NODM | ||||
Age | 0.988 (0.976–1.000) | 0.052 | ||
Male gender | 1.307 (0.848–2.013) | 0.225 | ||
Glucose | 1.009 (1.006–1.011) | < 0.001 | 1.009 (1.006–1.011) | < 0.001 |
Triglyceride | 1.001 (1.000–1.002) | 0.011 | 1.001 (1.000–1.002) | 0.021 |
β blocker | 0.768 (0.517–1.139) | 0.189 | ||
Statin type | 1.098 (0.808–1.491) | 0.551 | ||
MACE | ||||
Age | 1.026 (1.016–1.037) | < 0.001 | 1.020 (1.009–1.032) | 0.001 |
Male gender | 0.964 (0.695–1.336) | 0.824 | ||
LVEF | 0.974 (0.961–0.986) | < 0.001 | 0.980 (0.966–0.993) | 0.003 |
Glucose | 1.003 (1.000–1.006) | 0.089 | ||
Creatinine | 1.155 (1.080–1.235) | < 0.001 | 1.204 (1.062–1.364) | 0.004 |
LDL cholesterol | 0.995 (0.992–0.999) | 0.011 | 0.998 (0.994–1.002) | 0.258 |
Statin type | 0.944 (0.727–1.225) | 0.662 | ||
Ticagrelor or prasugrel | 0.685 (0.522–0.899) | 0.006 | 0.784 (0.585–1.051) | 0.104 |
ACEi or ARB | 0.761 (0.569–1.018) | 0.066 | ||
β blocker | 0.855 (0.609–1.201) | 0.367 | ||